The effects of raloxifene on mammographic breast density: A review of clinical trials

Menopause

Volumn 17, Issue 3, 2010, Pages 654-659

  Pearman, Leny ^a   Kagan, Risa ^b   Arsenault, Jody ^a   Muram, David ^a  

^a Lilly USA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Breast density; Raloxifene

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PLACEBO; RALOXIFENE; TIBOLONE;

BONE DENSITY; BREAST; BREAST CANCER; CLINICAL TRIAL; DENSITY; DRUG ACTIVITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN THERAPY; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; MAMMOGRAPHY; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK ASSESSMENT;

ADULT; BREAST; BREAST NEOPLASMS; CONTROLLED CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MAMMOGRAPHY; MENOPAUSE; MIDDLE AGED; RALOXIFENE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; WOMEN'S HEALTH;

EID: 77952275946     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181c29e56     Document Type: Review

References (35)

1. Egan RL, Dolan PD. Optical spectroscopy. Pre-mammography marker. Acta Radiol 1988;29:497-503.
2. Tice JA, Cummings SR, Ziv E, Kerlikowske K. Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat 2005;94:115-122.
3. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1159-1169.
4. Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mam-mography. J Natl Cancer Inst 2006;98:1204-1214.
5. Chen J, Pee D, Ayyagari R, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 2006;98:1215-1226.
6. Palomares MR, Machia JR, Lehman CD, Daling JR, McTiernan A. Mammographic density correlation with Gail model breast cancer risk estimates and component risk factors. Cancer Epidemiol Biomarkers Prev 2006;15:1324-1330.
7. Kerlikowske K, Shepherd J, Creasman J, Tice JA, Ziv E, Cummings SR. Are breast density and bone mineral density independent risk factors for breast cancer? J Natl Cancer Inst 2005;97:368-374.
8. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356:227-236.
9. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337: 1641-1647.
10. Freedman M, San Martin J, O'Gorman J, et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst 2001;93:51-56.
11. Bryant HU, Dere WH. Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proc Soc Exp Biol Med 1998;217:45-52.
12. Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 2008;63:163-181.
13. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-2197.
14. Evista [package insert]. Indianapolis, IN: Eli Lilly & Company; 1997.
15. Nolvadex (tamoxifen citrate) [package insert]. Wilmington, DE: Astra-Zeneca Pharmaceuticals; 2007.
16. Atkinson C, Warren R, Bingham SA, Day NE. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 1999;8:863-866.
17. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004;96:621-628.
18. Chow CK, Venzon D, Jones EC, Premkumar A, O'Shaughnessy J, Zujewski J. Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev 2000;9:917-921.
19. Cuzick J, Warwick J, Pinney L, et al. Change in breast density as a biomarker of breast cancer risk reduction; results from IBIS-1. Cancer Res 2009;69:61.
20. Jackson VP, San Martin JA, Secrest RJ, et al. Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammo-graphic breast density and breast tenderness in postmenopausal women. Am J Obstet Gynecol 2003;188:389-394.
21. Eilertsen AL, Karssemeijer N, Skaane P, Qvigstad E, Sandset PM. Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method. BJOG 2008;115:773-779.
22. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, Panoulis KP, Kelekis DA, Creatsas GC. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause 2002;9:110-116.
23. Lasco A, Gaudio A, Morini E, et al. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women. Menopause 2006;13:787-792.
24. Cirpan T, Akercan F, Itil IM, Gundem G, Bilgen I, Yucebilgin MS. Does raloxifene therapy affect mammographic breast cancer screening in postmenopausal patients? Eur J Gynaecol Oncol 2006;27:177-178.
25. Eng-Wong J, Orzano-Birgani J, Chow CK, et al. Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17:1696-1701.
26. Wolfe JN. Risk for breast cancer development determined by mammo-graphic parenchymal pattern. Cancer 1976;37:2486-2492.
27. Wolfe JN. Breast patterns as an index of risk for developing breast cancer. AJR Am J Roentgenol 1976;126:1130-1137.
28. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 2001;76:231-238.
29. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes; the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741.
30. Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 2004; 230:29-41.
31. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-645.
32. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-3617.
33. Cauley J, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE Trial. Breast Cancer Res Treat 2001;65:125-134.
34. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing Outcomes Relevant to Evista: breast cancer incidence in postmenopausal osteopo-rotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-1761.
35. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137. (Pubitemid 44050394)